Golden Helix Newsletter

 

A Hitchhiker's Guide to Next Generation Sequencing - Part 3
by Gabe Rudy, VP of Product Development A Hitchhikers Guide to Next Generation Sequencing  Part 3

Biologists, geneticists, clinicians, and pretty much any researcher with questions about our genetic code can now more affordably and capably than ever get DNA samples sequenced and processed in their pursuit for answers. Yes, this new-found technology produces unwieldy outputs of data. But thankfully, as raw data is processed down to just the differences between genomes, we are dealing with rich and accurate information that can easily be handled by researchers on their own terms.

In this final installment of the Hitchhiker's Guide to Next Generation Sequencing, I'm going to explore in more depth the workflows of tertiary analysis, focusing primarily on genotypic variants. Over the last three to four years, the scientific community has proposed a set of methods and tools for us to review as we explore the current landscape of solutions. So let's examine the current state of sense making, how the field is progressing, and the challenges that lay ahead. Continue reading on "Our 2 SNPs" »

Did you miss Parts 1 and 2?

Part 2
In this post I plan to explore, in depth, what goes into the analysis of sequence data and why both the cost and complexity of the bioinformatics should not be ignored. Whether you plan to send samples to a sequencing-as-a-service center, or brave the challenges of sequencing samples yourself, this post will help distinguish the fundamental difference in analyses by their usage patterns and complexity. Continue reading on "Our 2 SNPs" »


Part 1
In a series of three blog posts, I'm going to cover the evolution of sequencing technologies as a research tool, the bioinformatics of getting raw sequence data into something you can use, and finally the challenges and unmet needs Golden Helix sees in the sense-making of that processed sequence data. To start with, let's look at the story of how we got to where we are today. If you ever wondered what’s the difference between an Illumina HiSeq 2000 and a SOLiD 4hq, or why it seems that every six months the purported cost of whole genome sequencing is halved, then this story is for you. Continue reading on "Our 2 SNPs"»

 
   SVS 7.4 COMING SOON
With over 30 new features, the fourth installment of SNP & Variation Suite 7 will empower you to explore your data as never before.

Here's what you can expect to see next Thursday:
  • Breakthrough tertiary analyses for next-generation sequencing data
  • New state-of-the-art GWAS and CNV quality assurance
  • Significantly faster, and more in-depth copy number workflows
  • More powerful genome browsing and annotation track management
  • On-demand, advanced feature development with improved Python
  • Productivity enhancers

Join us for an exclusive look at 7.4!

Our VP of Product Development, Gabe Rudy, and Director of Services, Bryce Christensen, will be giving a webcast on the new features and functionality of SVS 7.4 on Wednesday, February 2nd at noon EST.

FEB
2
  Wed, February 2
12:00 pm EST

Webcast Registration



 


Recent Customer Success Highlights

 

11.25.10  |  International Journal of Immunogenetics
Toll-like receptor 1 gene polymorphisms in childhood IgA nephropathy: a case-control study in the Korean population
Lee, J et al.
Kyung Hee University, Seoul, Korea
Read the abstract »

 

12.8.10  |  European Journal of Human Genetics
Replication of genetic variants from genome-wide association studies with metabolic traits in an island population of the Adriatic coast of Croatia
Karns, R. et al
University of Cincinnati College of Medicine, Ohio
Read the abstract »

12.8.10  |  Neuropsychopharmacology
Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse
Moyer, R. et al.
Ohio State University, Ohio
Read the abstract »

12.16.10  |  PLoS ONE
Microarray-Based Maps of Copy-Number Variant Regions in European and Sub-Saharan Populations
Vogler, C. et al.
University of Basel, Switzerland
Read the abstract »

12.20.10  |  Pediatric Research
Linkage and Association Study of Neurotrophins and their receptors as Novel Susceptibility Genes for Childhood IgA Nephropathy
Hahn, W. et al.
Kyung Hee University, Seoul, Korea
Read the abstract »

12.22.10  |  Neuroscience Letters
Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects?
Souza, R. et al.
Centre for Addiction & Mental Health, Toronto, Canada
Read the abstract »


 
About Golden Helix
We are inspired by significance. Not only statistical, but technological, scientific, and personal significance. It's embodied in everything we and our customers do. And we believe the only way to achieve significance is by transcending the status quo. Every day we strive for extraordinary analytic and technological advancements that empower scientists around the world to pursue that which is truly significant: from uncovering the genetic causes of disease and transforming drug discovery to developing genetic diagnostics and advancing the quest for personalized medicine. To learn more about how we are accelerating the quest for significance visit www.goldenhelix.com.

 


Copyright 2000-2011 Golden Helix, Inc. All Rights Reserved.
Golden Helix, Inc. | 203 Enterprise, Blvd. | Bozeman, MT | 59718